Stalled Promise: The 15‑Year‑Old Ebola Vaccine That Could Turn the Tide

In the spring of 2011, a team at the National Institute of Allergy and Infectious Diseases announced a recombinant vesicular‑stomatitis virus (rVSV) vaccine designed to protect against Zaire ebolavirus. The candidate showed robust immunogenicity in early animal studies and entered Phase I human trials, where it demonstrated safety and modest antibody responses. Yet, after the 2014 West Africa epidemic diverted global attention, funding dwindled, and the vaccine was effectively shelved for a decade and a half. The vaccine’s efficacy was demonstrated in early Phase I trials, showing robust neutralizing antibody responses and a favorable safety profile. Yet, after promising initial results, funding dried up, manufacturing scale‑up stalled, and regulatory pathways were never fully pursued, leaving the candidate in a limbo that has persisted for a decade and a half. The rVSV platform, while technically mature, requires cold‑chain logistics and specialized production facilities that have been under‑invested in since the 2011 announcement. The current Bundibugyo episode, though smaller than the 2014 West Africa crisis, underscores the fragility of global health preparedness; a vaccine that could have been deployed a decade ago now faces a race against an evolving pathogen and limited logistical capacity in a region where health infrastructure remains under‑resourced. Recent WHO declarations highlight the need for rapid response assets, yet the absence of a licensed filovirus vaccine forces reliance on experimental ring‑vaccination strategies that are difficult to implement at scale. If the trial succeeds, the rVSV platform could revitalize pipelines for filovirus countermeasures, prompting renewed investment and policy attention. However, the episode also warns that delayed translation of scientific breakthroughs into deployable tools undermines the equity and speed that global health initiatives promise. Realizing the vaccine’s potential will require coordinated financing, streamlined regulatory pathways, and a commitment to equitable distribution once the outbreak is contained.